Health Informatics of Oxycodone Hydrochloride Sustained-Release Tablets for Cancer Pain Treatment with Support of Computed Tomography Diagnosis

Objective: The purpose of this study is to analyze the medical value of oxycodone hydrochloride sustainedrelease tablets in the treatment of advanced cancer pain in adults using biostatistics and computed tomography (CT). Methods: The efficacy, pain relief and adverse reactions of oxycodone hydrochloride sustained-release tablets in 100 patients with moderate to severe adult cancer pain were retrospectively analyzed. To compare the effects of gender, first-visit pain degree, pain type and metastasis on the effectiveness and pain relief. VAS score decreased by 25.0% or more is effective for treatment, in which pain disappeared completely for complete relief, VAS score decreased by 75.0% or more for obvious relief, VAS score decreased by 50.0%–74.9% for moderate relief, VAS score decreased by 25.0%–49.9% for mild relief, and VAS score decreased by less than 25.0% for no relief. Results: The pain relief rate was 93%. There were 12 cases of complete relief, 24 cases of obvious relief (32%), 23 cases of moderate relief (31%), 10 cases of mild relief (14%) and 5 cases of no relief (7%). The incidence of adverse reactions in patients was 56% constipation, 40% nausea and 76% vomiting. After 4 weeks, the incidence of adverse reactions in patients was 24% constipation, 13% nausea and 43% vomiting. Furthermore, CT image analysis shows that oxycodone hydrochloride sustained-release tablets has obvious therapeutic effect on cancer. Discussion: High-dose oxycodone sustained-release tablets are effective in the treatment of patients with advanced cancer pain. It can relieve the pain of patients, and has high safety. This can be verified based on our health informatics analysis and CT image diagnosis. Conclusion: Oxycodone hydrochloride sustained release tablets are effective and safe in the outpatient treatment of moderate and severe cancer pain in adults, and have better control effect on moderate cancer pain patients, which is worthy of further application and promotion for clinical use.